Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 236,696,854 papers from all fields of science
Search
Sign In
Create Free Account
pacritinib
Known as:
Oral JAK2 Inhibitor SB1518
An orally bioavailable inhibitor of Janus kinase 2 (JAK2) and the JAK2 mutant JAK2V617F with potential antineoplastic activity. Oral JAK2 inhibitor…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
NCIt Antineoplastic Agent Terminology
Receptor Tyrosine Kinase Inhibition
Narrower (1)
SB 1518
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Compositions and methods for treatment of vitiligo
S. D. Shanler
,
E. Dick
,
Neal Walker
,
C. Powala
2018
Corpus ID: 191167189
Methods of treating vitiligo using JAK/STAT modulating compounds are provided herein. The JAK/STAT modulating compounds may be…
Expand
2018
2018
Pacritinib May Benefit Patients with Myelofibrosis and Thrombocytopenia
J. Schieszer
2018
Corpus ID: 164706060
A recent phase III study revealed a benefit with pacritinib for patients with myelofibrosis and thrombocytopenia who have…
Expand
2017
2017
Pacritinib Induced Reduction in Splenomegaly, Myelofibrosis Symptoms
L. Lawrence
2017
Corpus ID: 181795708
The JAK2 and FLT3 inhibitor pacritinib induced significant and sustained spleen volume reduction and symptom reduction in…
Expand
2016
2016
Abstract CT159: Investigation of the absorption, metabolism, excretion, and mass balance of [14C]-pacritinib in healthy subjects: a phase I study
Suliman I. Al-Fayoumi
,
S. Amberg
,
Huafeng Zhou
,
L. Millard
,
J. Singer
,
J. Dean
2016
Corpus ID: 78247497
Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA Introduction: Dysregulation in tyrosine kinase…
Expand
2016
2016
Abstract 2602: The nonclinical toxicology profile of pacritinib, a JAK2/FLT3 inhibitor with no dose-limiting clinical myelosuppression
R. Watson
,
Suliman I. Al-Fayoumi
2016
Corpus ID: 78144964
Pacritinib is an orally active kinase inhibitor being developed for the treatment of myelofibrosis (MF). Pacritinib is a…
Expand
2015
2015
PERSIST-1: A PHASE III STUDY OF PACRITINIB (PAC) VS BEST AVAILABLE THERAPY (BAT) IN PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MF (PPV-MF) OR POST-ESSENTIAL THROMBOCYTHEMIA MF (PET-MF)
C. Harrison
,
A. Szoke
,
+20 authors
R. Mesa
2015
Corpus ID: 74799779
2015
2015
Expression and prognostic impact of long non-coding RNAs in acute myeloid leukemia
N. Curto-Garcia
2015
Corpus ID: 116627148
T discovery of JAK2 mutation a decade ago has marked a crucial change in our understanding and knowledge of the pathogenesis…
Expand
2015
2015
Pacritinib Bests Available Therapies for Myelofibrosis.
Cancer Discovery
2015
Corpus ID: 30149526
2014
2014
UK boosts discovery tools
G. Sinha
Nature Biotechnology
2014
Corpus ID: 45826921
119 The US Food and Drug Administration put a clinical hold on all trials of Sanofi’s fedratinib, a highly selective JAK2…
Expand
2012
2012
nonaene ( SB 1578 ) , a Potent Inhibitor of Janus Kinase 2 / Fms-LikeTyrosine Kinase-3 ( JAK 2 / FLT 3 ) for the Treatment of Rheumatoid Arthritis
A. William
,
Angeline Lee
,
+14 authors
B. Dymock
2012
Corpus ID: 207767842
Herein, we describe the synthesis and SAR of a series of small molecule macrocycles that selectively inhibit JAK2 kinase within…
Expand